At the insistence of regulators, Sprout Pharmaceuticals has recanted statements made in a press release last week that indicated the Food and Drug Administration had eased various restrictions concerning its controversial female libido pill.

The Sept. 4 press release maintained the agency removed a ban on the use of alcohol with the Addyi pill, a point of contention between Sprout and the FDA for the past few years. The release also suggested the FDA eliminated a safety requirement that physicians and pharmacists had to be certified to prescribe and dispense the medicine, respectively.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy